S-1: Klotho Neurosciences Files for Resale of Up to 43.7 Million Common Shares

Klotho Neurosciences is registering for resale up to 43.7 million shares of common stock, including shares issuable upon conversion of notes and exercise of warrants, by existing shareholders.

Summary

• Klotho Neurosciences has filed a registration statement for the resale of up to 43,680,219 shares of its common stock.
• This includes up to 37,876,100 shares that may be issued to investors upon conversion of promissory notes and exercise of warrants, and 5,804,119 shares currently held by selling shareholders.
• The offering price is estimated at $0.43 per share, based on the average of the high and low sales prices on January 27, 2025.
• The company will not receive any proceeds from the resale of these shares; all net proceeds will go to the selling stockholders.
• Klotho may receive proceeds from the exercise of warrants if they are not exercised on a cashless basis, potentially amounting to approximately $2 million if all warrants are exercised for cash.
• The company's common stock is traded on the NASDAQ Global Market under the symbol KLTO.

Sentiment

Score: 3

Explanation: The document is primarily a risk disclosure, highlighting the company's financial challenges, dependence on external factors, and the competitive landscape. While there is potential for future gains, the overall tone is cautious and indicates a high level of investment risk.

Positives

• The registration allows existing shareholders to sell their shares, potentially increasing liquidity.
• The potential exercise of warrants could provide the company with up to $2 million in capital.
• The company has a listing on the NASDAQ Global Market, providing access to a broader investor base.

Negatives

• The company will not receive any proceeds from the resale of shares by the selling stockholders.
• The large number of shares being registered for resale could put downward pressure on the stock price.
• The document highlights the high degree of risk associated with investing in the company's common stock, including the potential for complete loss of investment.

Risks

• The company has incurred significant losses since its inception and expects to continue incurring losses.
• The company will need substantial additional funding to meet its financial obligations and pursue its business objectives.
• The company is highly dependent on collaborations with Reliance Life Sciences Ltd. and Universitat Autnoma de Barcelona.
• Negative public opinion of gene therapy and increased regulatory scrutiny may adversely impact the company.
• The company faces significant competition in the area of biosimilar biologics.
• The company is dependent on the success of its biosimilar and gene therapy product candidates, which are still in early stages of development.
• The company may not be able to obtain regulatory approval for its product candidates.
• The company's product candidates may cause undesirable side effects.
• The company may be subject to product liability lawsuits.
• The company may not be able to maintain insurance coverage at a reasonable cost.
• The company may not be able to attract or retain qualified management and commercial, scientific and clinical personnel.
• The company's employees, independent contractors, principal investigators, consultants, commercial collaborators, manufacturers, service providers and other vendors, or those of its affiliates, may engage in misconduct or other improper activities.
• The company's international operations expose it to business, regulatory, political, operational, financial and economic risks.
• The company may infringe or be alleged to infringe intellectual property rights of third parties.
• The company may not be successful in its efforts to identify, develop or commercialize additional product candidates.
• The company may be subject, directly or indirectly, to federal and state healthcare laws and regulations.
• The company may fail to comply with environmental, health and safety laws and regulations.
• The company is subject to a variety of stringent and changing privacy and data security laws.
• The occurrence of the COVID-19 pandemic may negatively affect the company's operations.
• The company may in the future issue more shares that could cause a loss of control by its present management and current stockholders.
• The elimination of personal liability of director and officers under Delaware law and the existence of indemnification rights held by the company's directors, officers and employees may result in substantial expenses.
• The company may undertake one or more significant corporate transactions that may not achieve their intended results.
• The company is an emerging growth company and may take advantage of certain exemptions from various reporting requirements.
• The company has not paid dividends to date and does not intend to pay any dividends in the near future.
• If large amounts of the company's common shares held by its existing stockholders are sold in the future, the market price of the company's common shares could decline.
• Investors may suffer substantial dilution or an unrealized loss of seniority in preferences and privileges if the company needs to seek additional funding in the future.
• The company may need additional capital in the future, which may not be available to it on favorable terms, or at all, and may dilute your ownership of the company's common stock.
• The company may expand through acquisitions of, or investments in, other companies or through business relationships, all of which may result in additional dilution to its stockholders and consumption of resources that are necessary to sustain its business.
• Resales of shares purchased by the Selling Stockholders may cause the market price of the company's common stock to decline.
• If the company fails to comply with the continued listing requirements of Nasdaq, it may face possible delisting.

Future Outlook

The company expects to continue to incur significant operating and net losses, as well as negative cash flows from operations, for the foreseeable future as it continues to develop its gene therapy product candidates and prepare for potential future regulatory approvals and commercialization of its products.

Industry Context

The document indicates that the company operates in the competitive pharmaceutical and biotechnology markets, particularly in biosimilars and gene therapy, where numerous companies are engaged in developing and marketing similar products.

Comparison to Industry Standards

• The document mentions several competitors in the biosimilar market, including Sandoz, Hospira, Amgen, Pfizer, Boehringer Ingelheim, Teva, Samsung Bioepis, and Celltrion, all of which have greater resources and experience.
• The company's biosimilar product candidates will face competition from both the original branded versions and other already-approved biosimilar products.
• The company's gene therapy product candidates are based on new gene transfer technology, which makes it difficult to predict the time and cost of product candidate development and of subsequently obtaining regulatory approval.
• The document notes that only a limited number of gene therapies have received marketing authorization from the FDA or foreign regulatory authorities.

Stakeholder Impact

• Shareholders face a high degree of risk, including the potential for complete loss of investment.
• Employees may be affected by the company's financial challenges and potential need for additional funding.
• Customers may be impacted by the company's ability to develop and commercialize its product candidates.
• Suppliers and creditors may be affected by the company's financial stability and ability to meet its obligations.

Next Steps

• The company plans to complete the animal toxicology package for AMI-202 and submit an Investigational New Drug application (IND) to the FDA in 2025 for permission to start the first-in-human Phase I Compassionate Use study of AMI-202 in late-stage ALS patients.
• The company plans to find a corporate partner to help in the development of AMI-101 for the Alzheimers disease indication.
• The company may also bring the recombinant s-KL protein into clinical trials to evaluate the safety and efficacy of infusing the protein into normal healthy volunteers for pharmacology (PK/PD) and safety, and then in select patient populations.

Key Dates

Keywords

common stock, resale, promissory notes, warrants, biosimilar, gene therapy, neurodegenerative diseases, biologics, pharmaceutical, NASDAQ